Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -856.00K | 0.00 | -3.27M | -3.31M | -3.41M | -667.00K |
EBITDA | -181.29M | -134.75M | -141.57M | -143.49M | -128.57M | -62.80M |
Net Income | -167.38M | -138.20M | -134.24M | -138.29M | -127.79M | -62.74M |
Balance Sheet | ||||||
Total Assets | 303.03M | 350.07M | 297.67M | 285.10M | 287.04M | 355.95M |
Cash, Cash Equivalents and Short-Term Investments | 263.70M | 312.02M | 259.72M | 242.66M | 242.72M | 351.21M |
Total Debt | 28.31M | 28.97M | 31.36M | 32.86M | 34.59M | 0.00 |
Total Liabilities | 59.24M | 56.97M | 47.12M | 53.90M | 55.13M | 11.67M |
Stockholders Equity | 243.79M | 293.11M | 250.56M | 231.19M | 231.91M | 344.28M |
Cash Flow | ||||||
Free Cash Flow | -139.88M | -118.02M | -121.33M | -122.83M | -107.76M | -53.55M |
Operating Cash Flow | -139.79M | -118.01M | -121.14M | -116.31M | -106.11M | -53.09M |
Investing Cash Flow | -43.88M | -218.80M | 70.70M | 58.44M | -88.24M | -83.16M |
Financing Cash Flow | 128.85M | 161.21M | 135.52M | 122.91M | 1.79M | 360.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $373.54M | ― | -0.23% | ― | 3087.25% | 97.11% | |
61 Neutral | $617.85M | ― | -61.35% | ― | 10.10% | -7.25% | |
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
47 Neutral | $129.30M | ― | -262.12% | ― | 239.92% | 79.41% | |
45 Neutral | $165.44M | ― | -160.99% | ― | -75.67% | -552.37% | |
44 Neutral | $239.21M | ― | 2152.93% | ― | ― | ― | |
38 Underperform | $317.07M | ― | -66.13% | ― | ― | 43.21% |
Annexon Biosciences has appointed William Jones to its Board of Directors, bringing his extensive 30-year experience in the biotechnology industry to the company. This strategic move comes as Annexon prepares for the commercialization of key treatments for Guillain-Barré Syndrome and geographic atrophy, with Jones’ commercial expertise expected to enhance the company’s market positioning and execution of its commercialization strategies.